Target- and Mechanism-Based Therapeutics for Neurodegenerative Diseases: Strength in Numbers

详细信息    查看全文

• 作者：Paul C. Trippier ; Kristin Jansen Labby ; Dustin D. Hawker ; Jan J. Mataka ; Richard B. Silverman
• 刊名：Journal of Medicinal Chemistry
• 出版年：2013
• 出版时间：April 25, 2013
• 年：2013
• 卷：56
• 期：8
• 页码：3121-3147
• 全文大小：966K
• 年卷期：v.56,no.8(April 25, 2013)
• ISSN：1520-4804

文摘

The development of new therapeutics for the treatment of neurodegenerative pathophysiologies currently stands at a crossroads. This presents an opportunity to transition future drug discovery efforts to target disease modification, an area in which much still remains unknown. In this Perspective we examine recent progress in the areas of neurodegenerative drug discovery, focusing on some of the most common targets and mechanisms: N-methyl-class="smallcaps">d-aspartic acid (NMDA) receptors, voltage gated calcium channels (VGCCs), neuronal nitric oxide synthase (nNOS), oxidative stress from reactive oxygen species, and protein aggregation. These represent the key players identified in neurodegeneration and are part of a complex, intertwined signaling cascade. The synergistic delivery of two or more compounds directed against these targets, along with the design of small molecules with multiple modes of action, should be explored in pursuit of more effective clinical treatments for neurodegenerative diseases.